Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

PLoS One · 2016 · PMC4783083 · PMID 26954503

Europe PMC DOI

hedged sentence

0.3430

closest p · 6.9× alpha

0.3430

boldest claim

The sentences

a slight trendp = 0.343not close (p > 0.1)

bevacizumab group, pemetrexed did not exhibit an obvious change in PFS (HR = 0.96, p = 0.752; I 2 = 35.8%, p = 0.212) or OS (HR = 0.98, p = 0.744, I 2 = 0.0%) but exhibited a slight trend to reduce grade 3–4 AEs (HR = 0.79, p = 0.343, I 2 = 65.7, p = 0.088).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.